ELE-101 is an intravenous synthetic formulation of psilocin, the active metabolite of psilocybin. Credit: christopher lemercier / Unsplash.

Clinical-stage biotechnology firm Beckley Psytech has dosed the first subject in its Phase I trial of the new short-acting psychedelic compound ELE-101.

The randomised, placebo-controlled, double-blind study has been designed to evaluate the tolerability, pharmacodynamic (PD), safety, pharmacokinetic (PK) profile, and subjective drug intensity (SDI) of ELE-101 single ascending intravenous doses in up to 60 healthy adults.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

ELE-101 is an intravenous synthetic formulation of psilocin, the active psilocybin metabolite, to treat major depressive disorder (MDD).

It can provide a more consistent and controllable response in patients, with a quick onset, significantly less treatment duration and variability compared to oral formulations of psilocybin.

The company added ELE-101 to its portfolio after purchasing Eleusis Therapeutics last month.

See Also:

Beckley Psytech CEO Cosmo Feilding Mellen said: “This is an important milestone for Beckley Psytech and demonstrates our commitment to positively disrupt the way depression and other neuropsychiatric conditions are treated.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“It also reflects our commitment to exploring novel, shorter-acting formulations of psychedelic compounds, which, we believe, will provide a more accessible treatment option with a lower burden on both patients and healthcare systems.

“We are optimistic about the potential of ELE-101 and look forward to evaluating the compound in future studies.”

The company expects to receive the complete results of the study in the first half of next year.

It intends to use the blinded data to help design a Phase IIa study, which is planned to commence during the same period.

Beckley Psytech team expects that ELE-101 has the potential to address a few observed limitations of oral psilocybin, including long duration of action and variability in responses of patients.